PharmaEssentia Corporation Stock

Equities

6446

TW0006446008

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. 2025-02-07 5-day change 1st Jan Change
699.00 TWD -1.27% Intraday chart for PharmaEssentia Corporation +1.75% +13.66%

Valuation: PharmaEssentia Corporation

Capitalization 233B 7.09B 6.85B 6.45B 5.72B 10.15B 622B 11.32B 77.5B 28.8B 255B 26.58B 26.04B 1,072B P/E ratio 2024 *
83.2x
P/E ratio 2025 * 38.7x
Enterprise value 213B 6.5B 6.29B 5.91B 5.24B 9.31B 570B 10.38B 71.11B 26.42B 234B 24.38B 23.89B 983B EV / Sales 2024 *
22.4x
EV / Sales 2025 * 14.2x
Free-Float
74.32%
Yield 2024 *
0.37%
Yield 2025 * 0.45%
More valuation ratios * Estimated data
Dynamic Chart
PharmaEssentia Corp Announces China NMPA has Accepted the Phase III Clinical Trial Application of P1101 for Pre-fibrotic/Early PMF or Overt PMF at Low or Intermediate-1 Risk Jan. 13 CI
PharmaEssentia Corporation Announces Positive Topline Phase 3 Data from Surpass-ET Study Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia Jan. 06 CI
PharmaEssentia Corporation Announces Positive Topline Results from Phase 3 Clinical Trial of P1101 for ET Jan. 03 CI
Pharmaessentia Corp. Submits Phase III Clinical Trial of P1101 for Pre-fibrotic/Early PMF or Overt PMF at Low or Intermediate-1 Risk to China NMPA Jan. 03 CI
MOHW Requests Supplementary Information for PharmaEssentia's Clinical Trial Application for Tumor Therapy Jan. 03 MT
PharmaEssentia Corporation Announces Update on its IND Application of Phase I Clinical Trial of TCRT-ESO-A2-TW in Patients with Advanced Solid Tumors to TFDA Jan. 02 CI
Brazil ANVISA Completes the GMP Inspection of PharmaEssentia's DS Manufacturing Plant in Taichung Dec. 06 CI
Pharmaessentia Corporation Appoints Joseph R. Horvat as Global Chief Commercial Officer Dec. 05 CI
PharmaEssentia Corporation Announces Nine Data Presentations at ASH Annual Meeting Nov. 25 CI
PharmaEssentia Logs NT$1.73 Billion Profit in January-September Period Nov. 14 MT
PharmaEssentia Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 14 CI
PharmaEssentia Corp. Announces Last Patient Last Visit of the Phase III Clinical Trial of Ropeginterferon Alfa-2b for Essential Thrombocythemia Nov. 12 CI
PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of TCRT-ESO-A2-TW in Patients with Advanced Solid Tumors to TFDA Nov. 01 CI
More news
1 day-1.27%
1 week+1.75%
Current month+1.75%
1 month-3.98%
3 months+12.02%
6 months+5.75%
Current year+13.66%
More quotes
1 week
663.00
Extreme 663
717.00
1 month
663.00
Extreme 663
732.00
Current year
600.00
Extreme 600
734.00
1 year
281.00
Extreme 281
735.00
3 years
243.00
Extreme 243
735.00
5 years
53.60
Extreme 53.6
735.00
10 years
45.16
Extreme 45.16
735.00
More quotes
Director TitleAgeSince
Chief Executive Officer - 2002-12-31
Director of Finance/CFO - 2015-10-13
Chief Tech/Sci/R&D Officer - -
Manager TitleAgeSince
Director/Board Member 76 2014-02-28
Director/Board Member - 2006-06-29
Chairman - 2003-08-31
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-1.27%+1.75%+125.85%+143.55% 7.09B
-2.46%+1.65%+10.93%+94.79% 121B
-1.67%+5.50%-24.98%+14.90% 75.99B
-0.94%-1.71%+74.01%+155.04% 39.71B
-1.94%-4.98%+24.98%-26.31% 28.2B
-2.35%-0.66%+56.42%+5.83% 23.85B
+0.21%+5.08%+9.51%-38.16% 22.87B
-2.71%-6.47%+381.10%+835.35% 14.83B
-1.03%+4.40%+179.84%+250.35% 14.3B
-18.53%-19.23%-8.78%+53.43% 12.41B
Average -3.27%-1.38%+82.89%+148.88% 36.01B
Weighted average by Cap. -2.39%+0.71%+37.87%+96.97%
See all sector performances

Financials

2024 *2025 *
Net sales 9.55B 291M 281M 265M 235M 417M 25.52B 465M 3.18B 1.18B 10.47B 1.09B 1.07B 44B 14.85B 452M 437M 411M 365M 648M 39.66B 722M 4.95B 1.84B 16.27B 1.7B 1.66B 68.39B
Net income 2.8B 85.33M 82.51M 77.59M 68.8M 122M 7.48B 136M 933M 347M 3.07B 320M 313M 12.9B 6.06B 185M 179M 168M 149M 264M 16.19B 295M 2.02B 750M 6.64B 692M 678M 27.92B
Net Debt -19.19B -585M -565M -532M -471M -837M -51.27B -934M -6.39B -2.38B -21.04B -2.19B -2.15B -88.41B -21.61B -658M -637M -599M -531M -943M -57.74B -1.05B -7.2B -2.67B -23.69B -2.47B -2.42B -99.56B
More financial data * Estimated data
Logo PharmaEssentia Corporation
PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the research and development of new drugs, which are used for treatment of hematology, such as meloproliferative neoplasms (MPN), neutropenia, anemia; infectious disease, such as hepatitis C and hepatitis B; dermatology, such as psoriasis, and neurology, such as multiple sclerosis, among others. The Company’s products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, PEG-EPO and others. The Company distributes its products within domestic market and to overseas markets.
Employees
131
More about the company
Date Price Change Volume
25-02-07 699.00 NT$ -1.27% 1,636,902
25-02-06 708.00 NT$ +4.12% 3,826,927
25-02-05 680.00 NT$ +1.49% 1,212,129
25-02-04 670.00 NT$ -0.89% 986,936

End-of-day quote Taiwan S.E., February 06, 2025

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
699.00TWD
Average target price
854.80TWD
Spread / Average Target
+22.29%
Consensus

Quarterly revenue - Rate of surprise